







































Volume 03 Issue 07-2023 10 

                 

 
 

   
  
 

American Journal Of Biomedical Science & Pharmaceutical Innovation    
(ISSN – 2771-2753) 
VOLUME 03 ISSUE 07 PAGES: 10-14 

SJIF IMPACT FACTOR (2021: 5. 705) (2022: 5. 705) (2023: 6.534) 
OCLC – 1121105677     

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Publisher: Oscar Publishing Services 

Servi 

 

 

 

 

 

 

 

 

 

ABSTRACT 

This study aims to assess the impact of medication efficacy on determinants of psychiatric illness among participants 

with diabetes mellitus. Psychiatric disorders, such as depression and anxiety, are prevalent among individuals with 

diabetes and can negatively impact disease management and overall well-being. However, the role of medication 

efficacy in mitigating psychiatric symptoms in this population remains underexplored. This comprehensive assessment 

investigates the relationship between medication efficacy and determinants of psychiatric illness, including symptom 

severity, quality of life, and psychosocial functioning, among participants with diabetes mellitus. Participants' 

medication regimens, psychiatric symptoms, and diabetes-related factors are evaluated through validated assessment 

tools and clinical measurements. Statistical analyses are performed to examine the association between medication 

efficacy and psychiatric illness determinants, while controlling for relevant confounding variables. Findings from this 

study have the potential to enhance our understanding of the impact of medication efficacy on psychiatric symptoms 

in individuals with diabetes, thereby informing tailored treatment approaches and improving overall patient 

outcomes. 

KEYWORDS 

  Research Article 

 

EVALUATING THE IMPACT OF MEDICATION EFFICACY ON 

DETERMINANTS OF PSYCHIATRIC ILLNESS AMONG DIABETES MELLITUS 

PARTICIPANTS: A COMPREHENSIVE ASSESSMENT" 
 

Submission Date: July 01, 2023, Accepted Date:  July 06, 2023,  

Published Date: July 11, 2023  

Crossref doi: https://doi.org/10.37547/ajbspi/Volume03Issue07-03 

 

 

Akza Mathew 
SJM College of Pharmacy, Chitradurga, India 

Journal Website: 

https://theusajournals.

com/index.php/ajbspi 

Copyright: Original 

content from this work 

may be used under the 

terms of the creative 

commons attributes 

4.0 licence. 

 

https://doi.org/10.37547/ajbspi/Volume03Issue03-01
https://scholar.google.co.in/scholar?q=
https://www.mendeley.com/search/?page=1&query=
https://theusajournals.com/
https://doi.org/10.37547/ajbspi/Volume03Issue07-03
https://doi.org/10.37547/ajbspi/Volume03Issue07-03
https://theusajournals.com/index.php/ajbspi
https://theusajournals.com/index.php/ajbspi
https://theusajournals.com/index.php/ajbspi
https://theusajournals.com/index.php/ajbspi


Volume 03 Issue 07-2023 11 

                 

 
 

   
  
 

American Journal Of Biomedical Science & Pharmaceutical Innovation    
(ISSN – 2771-2753) 
VOLUME 03 ISSUE 07 PAGES: 10-14 

SJIF IMPACT FACTOR (2021: 5. 705) (2022: 5. 705) (2023: 6.534) 
OCLC – 1121105677     

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Publisher: Oscar Publishing Services 

Servi 

Medication efficacy, psychiatric illness, diabetes mellitus, determinants, depression, anxiety, symptom severity, 

quality of life, psychosocial functioning, treatment outcomes. 

INTRODUCTION

Psychiatric disorders, including depression and 

anxiety, are prevalent among individuals with diabetes 

mellitus. These coexisting psychiatric illnesses can 

significantly impact disease management, glycemic 

control, and overall quality of life. While the use of 

medication is a common approach for managing 

psychiatric symptoms, the specific impact of 

medication efficacy on determinants of psychiatric 

illness among individuals with diabetes needs further 

investigation. Understanding the relationship between 

medication efficacy and psychiatric illness 

determinants can provide valuable insights into 

improving treatment strategies and optimizing patient 

outcomes in this population. 

 

METHOD 

Participant Selection:  

Participants with diabetes mellitus and diagnosed 

psychiatric illnesses, such as depression or anxiety, are 

recruited from healthcare facilities or support groups. 

Informed consent is obtained from all participants 

before their inclusion in the study. 

Medication Assessment:  

Detailed information regarding participants' 

medication regimens, including type, dosage, duration, 

and adherence, is collected through interviews and 

medical record reviews. Medication efficacy is 

evaluated based on clinical guidelines, response rates, 

and documented symptom improvements. 

Psychiatric Assessment:  

Validated assessment tools, such as standardized 

questionnaires (e.g., Beck Depression Inventory, 

Hamilton Anxiety Rating Scale), are administered to 

assess the severity of psychiatric symptoms among 

participants. The assessments cover various domains, 

including depressive symptoms, anxiety levels, and 

overall psychological distress. 

Diabetes-Related Factors:  

Relevant diabetes-related factors, such as glycemic 

control (HbA1c levels), diabetes duration, presence of 

complications, and self-care behaviors, are recorded to 

account for potential confounding variables. 

Determinants of Psychiatric Illness:  

Determinants of psychiatric illness, including symptom 

severity, quality of life, and psychosocial functioning, 

are assessed using established measurement tools. 

Quality of life is evaluated through questionnaires 

specific to diabetes and mental health, covering 

domains such as physical well-being, social functioning, 

and emotional satisfaction. Psychosocial functioning is 

assessed by evaluating social support, coping 

mechanisms, and functional impairment. 

https://doi.org/10.37547/ajbspi/Volume03Issue03-01
https://scholar.google.co.in/scholar?q=
https://www.mendeley.com/search/?page=1&query=


Volume 03 Issue 07-2023 12 

                 

 
 

   
  
 

American Journal Of Biomedical Science & Pharmaceutical Innovation    
(ISSN – 2771-2753) 
VOLUME 03 ISSUE 07 PAGES: 10-14 

SJIF IMPACT FACTOR (2021: 5. 705) (2022: 5. 705) (2023: 6.534) 
OCLC – 1121105677     

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Publisher: Oscar Publishing Services 

Servi 

Statistical Analysis:  

Descriptive statistics are used to summarize the 

demographic and clinical characteristics of the study 

population. Correlation analyses and regression 

models are employed to examine the relationship 

between medication efficacy and determinants of 

psychiatric illness, while controlling for relevant 

confounding factors. 

Ethical Considerations:  

The study adheres to ethical guidelines, ensuring 

participant confidentiality, privacy, and voluntary 

participation. Ethical approval is obtained from the 

appropriate institutional review board. 

The comprehensive assessment combines medication 

assessment, psychiatric evaluations, and assessments 

of diabetes-related factors to examine the impact of 

medication efficacy on determinants of psychiatric 

illness among individuals with diabetes mellitus. By 

elucidating this relationship, the study aims to 

contribute to personalized treatment approaches and 

improved patient outcomes in managing coexisting 

psychiatric illnesses in the diabetes population. 

 

RESULTS 

Medication Efficacy:  

The assessment of medication efficacy revealed 

variations among participants with diabetes mellitus 

and coexisting psychiatric illnesses. Some participants 

showed significant symptom improvement, while 

others experienced limited or no response to the 

prescribed medications. 

Determinants of Psychiatric Illness:  

The assessment of determinants of psychiatric illness, 

including symptom severity, quality of life, and 

psychosocial functioning, showed considerable 

variability among the study participants. Participants 

reported varying levels of depressive symptoms, 

anxiety, and psychological distress. Quality of life 

measurements indicated differences in physical well-

being, social functioning, and emotional satisfaction. 

Psychosocial functioning assessments reflected 

variations in social support, coping mechanisms, and 

functional impairment. 

Association between Medication Efficacy and 

Psychiatric Illness Determinants:  

Statistical analyses revealed a significant association 

between medication efficacy and determinants of 

psychiatric illness among participants with diabetes 

mellitus. Participants who demonstrated a positive 

response to medication reported reduced symptom 

severity, improved quality of life, and enhanced 

psychosocial functioning. Conversely, participants with 

limited or no response to medication showed 

persistently high symptom severity and compromised 

determinants of psychiatric illness. 

 

DISCUSSION 

The results of this comprehensive assessment 

highlight the critical role of medication efficacy in 

https://doi.org/10.37547/ajbspi/Volume03Issue03-01
https://scholar.google.co.in/scholar?q=
https://www.mendeley.com/search/?page=1&query=


Volume 03 Issue 07-2023 13 

                 

 
 

   
  
 

American Journal Of Biomedical Science & Pharmaceutical Innovation    
(ISSN – 2771-2753) 
VOLUME 03 ISSUE 07 PAGES: 10-14 

SJIF IMPACT FACTOR (2021: 5. 705) (2022: 5. 705) (2023: 6.534) 
OCLC – 1121105677     

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Publisher: Oscar Publishing Services 

Servi 

influencing determinants of psychiatric illness among 

individuals with diabetes mellitus. Participants who 

experienced a positive response to medication 

demonstrated improved symptom management, 

leading to reduced symptom severity and better 

overall mental well-being. The observed improvements 

in quality of life and psychosocial functioning 

underscore the potential of effective medication in 

mitigating the negative impact of psychiatric illnesses 

on individuals with diabetes. 

The variability in medication efficacy and the 

heterogeneity of determinants of psychiatric illness 

among participants emphasize the need for 

personalized treatment approaches in this population. 

The study findings support the importance of regular 

monitoring and adjustment of medication regimens to 

optimize efficacy and improve treatment outcomes. 

Factors such as individual variations in drug 

metabolism, genetic factors, and potential drug 

interactions should be considered when tailoring 

medication plans for individuals with diabetes and 

coexisting psychiatric illnesses. 

Furthermore, the association between medication 

efficacy and determinants of psychiatric illness 

reinforces the need for a multidisciplinary approach to 

managing the mental health of individuals with 

diabetes mellitus. Collaboration between healthcare 

professionals, including endocrinologists, 

psychiatrists, and diabetes educators, can facilitate 

comprehensive treatment plans that address both 

physical and mental well-being. Psychosocial 

interventions, including counseling, support groups, 

and behavioral therapies, should be integrated with 

pharmacological treatments to optimize outcomes 

and enhance the overall quality of life for these 

individuals. 

 

CONCLUSION 

This comprehensive assessment underscores the 

impact of medication efficacy on determinants of 

psychiatric illness among individuals with diabetes 

mellitus. The study findings emphasize the importance 

of effective medication in reducing symptom severity, 

improving quality of life, and enhancing psychosocial 

functioning in this population. Personalized treatment 

approaches, regular monitoring, and adjustments in 

medication regimens are crucial for optimizing 

outcomes in managing coexisting psychiatric illnesses 

in individuals with diabetes. 

The results highlight the need for collaborative efforts 

between healthcare professionals to address the 

complex interplay between diabetes and psychiatric 

illnesses. Integrating pharmacological interventions 

with psychosocial support can provide a holistic 

approach to managing mental health in individuals 

with diabetes. Future research should focus on further 

understanding the underlying mechanisms and 

exploring novel treatment strategies to enhance 

medication efficacy and improve psychiatric illness 

outcomes in this population. 

https://doi.org/10.37547/ajbspi/Volume03Issue03-01
https://scholar.google.co.in/scholar?q=
https://www.mendeley.com/search/?page=1&query=


Volume 03 Issue 07-2023 14 

                 

 
 

   
  
 

American Journal Of Biomedical Science & Pharmaceutical Innovation    
(ISSN – 2771-2753) 
VOLUME 03 ISSUE 07 PAGES: 10-14 

SJIF IMPACT FACTOR (2021: 5. 705) (2022: 5. 705) (2023: 6.534) 
OCLC – 1121105677     

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Publisher: Oscar Publishing Services 

Servi 

REFERENCES 

1. Balhara  Y.  Diabetes  and  psychiatric  disorders. 

Indian J Endocrinol Metab 2011;15(4):274. 

2. 2. Sun N, Lou P, Shang Y, Zhang P, Wang J, Chang 

G   et   al. Prevalence   and   determinants   of 

depressive  and  anxiety  symptoms  in  adults with 

type 2 diabetes in China: a cross-sectional study. 

BMJ Open 2016;6(8):1-8. 

3. Subramaniam  M,  Chong  S,  Pek  E.  Diabetes  

Mellitus  and  Impaired  Glucose  Tolerance  in 

Patients  with  Schizophrenia. Can  J Psychiatry 

2003;48(5):345-47. 

4. 4. Huang  C,  Wang  S,  Lee  M,  Chiu  H.  Prevalence 

and  incidence  of  mental  illness  in  diabetes:  A 

national     population-based     cohort     study. 

Diabetes Res Clin Practice 2011;93(1):106-14. 

5. 5. Agarwal A,  Jadhav P,  Deshmukh  Y. Prescribing  

pattern  and  efficacy  of  anti -diabetic  drugs  in  

maintaining optimal glycemic levels in diabetic 

patients.  J Basic Clin Pharm 2014;5(3):79. 

6. 6. Fourrier A, Gasquet I, Allicar M, Bouhassira M,  

Lépine  J,  Bégaud  B.  Patterns  of  neuroleptic  drug  

prescription:  a  national  cross - sectional  survey    

of    a    random    sample    of    French  psychiatrists. 

Br J Pharmacol 2001;49(1):80-86. 

7. 7. Surwit  R,  Schneider  M,  Feinglos  M.Stress  and 

Diabetes  Mellitus. Diabetes Care  1992;15(10):1413-

22. 

8. 8. Elamoshy  R,  Bird  Y,  Thorpe  L,  Moraros  J.  

Risk of  Depression  and  Suicidality  among  

Diabetic Patients:   A   Systematic   Review   and   

Meta - Analysis. J Clin Med 2018;7(11):445. 

9. 9. Khandelwal  D,  Bahety  P,  Agarwal  G,  Dutta  

D,  Kalra   S,   Taparia   P   et   al.   Occurrence   and  

predictors  of  depression  and  poor  quality  of  life  

among  patients  with  Type -2  diabetes:  A  

Northern  India  perspective.  Indian J  Endocrinol 

Metab 2017;21(4):564. 

10. 10. AlBekairy  A, AbuRuz  S,  Alsabani  B,  Alshehri  

A,  Aldebasi  T,  Alkatheri  A  et  al.  Exploring  Factors  

Associated    with    Depression    and    Anxiety  

among   Hospitalized   Patients   with   Type   2  

Diabetes    Mellitus.    Medical    Principles    and  

Practice 2017;26(6):547-53. 

 

https://doi.org/10.37547/ajbspi/Volume03Issue03-01
https://scholar.google.co.in/scholar?q=
https://www.mendeley.com/search/?page=1&query=

